Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CTR002
MIFTS: 59

Cataract

Categories: Eye diseases, Fetal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cataract

About this section

MalaCards integrated aliases for Cataract:

Name: Cataract 39 12 77 38 30 56 6 44 45 15 41 17
Cataracts 64

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Fetal diseases Metabolic diseases
Anatomical: Eye diseases Nephrological diseases Oral diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:83
KEGG 38 H01202
ICD9CM 36 366.8
MeSH 45 D002386
UMLS 74 C0029531
Sources

Summaries for Cataract

About this section
PubMed Health : 64 About cataracts: A cataract is an eye condition in which the lens of the eye becomes cloudy. This causes vision to worsen, making it especially difficult to see fine details clearly. Some people’s vision is only slightly affected, whereas others might lose their eyesight very quickly. How it progresses will depend on things like the exact type of cataract. The word “cataract” comes from the Greek word for “waterfall” because in the past it was believed that the blurring was caused by a fluid in the eye.Cataracts mostly affect people over 50, and the risk increases with age: About 20 out of 100 people between the ages of 65 and 74 have a cataract. And more than 50 out of 100 people over the age of 74 are affected.Cataracts are the main cause of blindness in developing countries. The number of people who go blind from cataracts is considerably lower in industrialized countries due to the availability of effective surgery. Cataract surgery involves removing the cloudy eye lens and replacing it with an artificial lens. It is one of the most common surgical procedures performed in Germany, where about 800,000 people have cataract surgery every year.

MalaCards based summary : Cataract, also known as cataracts, is related to cataract 9, multiple types and cataract 16, multiple types. An important gene associated with Cataract is LIM2 (Lens Intrinsic Membrane Protein 2), and among its related pathways/superpathways is Protein processing in endoplasmic reticulum. The drugs Gabapentin and Dipivefrin have been mentioned in the context of this disorder. Affiliated tissues include Eye, eye and endothelial, and related phenotype is vision/eye.

Disease Ontology : 12 A lens disease characterized by clouding of the lens inside the eye which leads to a decrease in vision.

MedlinePlus : 44 A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision Frequent prescription changes in your eye wear Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute

Wikipedia : 77 A cataract is a clouding of the lens in the eye which leads to a decrease in vision. Cataracts often... more...

Sources

Related Diseases for Cataract

About this section

Diseases in the Cataract family:

Cataract 32, Multiple Types Cataract 7
Cataract 8, Multiple Types Cataract 4, Multiple Types
Cataract 29 Cataract 42
Cataract 20, Multiple Types Cataract 1, Multiple Types
Cataract 30, Multiple Types Cataract 41
Cataract 6, Multiple Types Cataract 5, Multiple Types
Cataract 46, Juvenile-Onset Cataract 40
Cataract 10, Multiple Types Cataract 24
Cataract 3, Multiple Types Cataract 14, Multiple Types
Cataract 9, Multiple Types Cataract 2, Multiple Types
Cataract 31, Multiple Types Cataract 25
Cataract 26, Multiple Types Cataract 27
Cataract 28 Cataract 35
Cataract 22, Multiple Types Cataract 18
Cataract 21, Multiple Types Cataract 23, Multiple Types
Cataract 11, Multiple Types Cataract 33, Multiple Types
Cataract 17, Multiple Types Cataract 12, Multiple Types
Cataract 47 Cataract 34, Multiple Types
Cataract 16, Multiple Types Cataract 36
Cataract 37 Cataract 38
Cataract 39, Multiple Types Cataract 15, Multiple Types
Cataract 19, Multiple Types Cataract 43
Cataract 44 Cataract 45
Cataract 48 Cataract 30
Cataract 33 Cataract Congenital Autosomal Dominant
Cataract, Total Congenital

Diseases related to Cataract via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1072)
# Related Disease Score Top Affiliating Genes
1 cataract 9, multiple types 34.6 CRYAA GJA8
2 cataract 16, multiple types 34.6 CRYAA CRYAB CRYBA1 CRYGC CRYGD CRYGS
3 cataract 1, multiple types 34.6 GJA3 GJA8
4 cataract 10, multiple types 34.6 CRYAB CRYBA1
5 cataract 30, multiple types 34.5 CRYGC CRYGD GJA3 GJA8
6 cataract 44 34.5 CRYAA GJA8 LIM2
7 cataract microcornea syndrome 34.4 CRYAA CRYGC CRYGD GJA8
8 cataract 24 34.4 CRYAA CRYBB3 CTAA2
9 cerulean cataract 34.3 CRYGD CTRCT37
10 cataract 14, multiple types 34.3 GJA3 GJA8
11 cataract 25 34.2 CRYBA1 CRYGS CTRCT25 GJA8
12 posterior polar cataract 34.2 CRYAB CRYBA1 CRYGD GJA3
13 nuclear senile cataract 34.0 CRYAA CRYGD CRYGS
14 mature cataract 33.9 CRYAA CRYGS
15 early-onset nuclear cataract 33.8 CRYAA CRYAB CRYBA1 CRYBB3 CRYGC CRYGD
16 warburg micro syndrome 32.2 CRYBB3 IARS2
17 presbyopia 30.9 CRYAA CRYGS
18 lens disease 30.8 CRYAA CRYAB CRYGD CRYGS GJA3 GJA8
19 hyperferritinemia with or without cataract 12.6
20 cataract 4, multiple types 12.6
21 cataract 21, multiple types 12.6
22 cataract 6, multiple types 12.5
23 cataract 3, multiple types 12.5
24 cataract 17, multiple types 12.5
25 cataract 2, multiple types 12.5
26 cataract 11, multiple types 12.5
27 cataract 22, multiple types 12.5
28 cataract 40 12.5
29 cataract 5, multiple types 12.5
30 cataract 23, multiple types 12.5
31 cataract 18 12.5
32 cataract 31, multiple types 12.5
33 cataract 34, multiple types 12.4
34 cataract 41 12.4
35 cataract 38 12.4
36 cataract 39, multiple types 12.4
37 cataract 12, multiple types 12.4
38 congenital cataracts, facial dysmorphism, and neuropathy 12.4
39 cataract 19, multiple types 12.4
40 cataract 15, multiple types 12.4
41 cataract 47 12.4
42 cataract 8, multiple types 12.4
43 cataract 30 12.4
44 cataract 29 12.4
45 3-methylglutaconic aciduria with cataracts, neurologic involvement, and neutropenia 12.4
46 cataract 43 12.4
47 cataract 7 12.4
48 cataract 32, multiple types 12.3
49 cataract 20, multiple types 12.3
50 myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay 12.3

Graphical network of the top 20 diseases related to Cataract:



Diseases related to Cataract
Sources

Symptoms & Phenotypes for Cataract

About this section

MGI Mouse Phenotypes related to Cataract:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.28 CRYAB CRYBA1 CRYGC CRYGD CRYGS GJA3
Sources

Drugs & Therapeutics for Cataract

About this section

PubMedHealth treatment related to Cataract: 64

Some people can compensate for the vision loss, temporarily or even in the longer term, by wearing glasses or contact lenses. There are no medications for the treatment of cataracts.The only effective treatment is surgery. Cataract surgery involves removing the cloudy lens and replacing it with a new, artificial lens. The lens capsule – an elastic membrane surrounding the lens of the eye – is left in the eye during surgery. Only the inner core and the outer cortex of the lens are broken up into small pieces using ultrasound. The pieces are then sucked out of the eye through a small cut. This procedure, called phacoemulsification, is the standard technique in Germany and some other countries. Once the lens has been removed, an artificial lens is implanted into the lens capsule.Whether and when surgery is an appropriate treatment option is very much a personal decision. The extent to which vision loss is affecting someone’s life will play a very important role. Another factor to consider is the presence of other (eye) conditions, which could affect the outcome of cataract surgery.

Drugs for Cataract (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 482)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 60142-96-3 3446
2
Dipivefrin Approved Phase 4,Phase 3,Not Applicable 52365-63-6 3105
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
4
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 57-63-6 5991
5
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
6
Norgestimate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 35189-28-7 6540478
7
Besifloxacin Approved Phase 4,Phase 1 141388-76-3
8
Moxifloxacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
9
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 1 82034-46-6, 129260-79-3 9865442 444025
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
12
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
14
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable 74103-06-3, 66635-83-4 3826
15
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 78281-72-8 151075
16
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 9004-61-9 53477741
17
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
19
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
21
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 32986-56-4 36294 5496
22
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
23
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
24
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
25
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 347396-82-1 459903
26
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 46507594 772
27
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 113775-47-6 5311068 68602
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
29
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 38396-39-3, 2180-92-9 2474
30
Diclofenac Approved, Vet_approved Phase 4,Phase 1,Not Applicable 15307-86-5 3033
31
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 216974-75-3
32
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
33
Tacrolimus Approved, Investigational Phase 4,Not Applicable 104987-11-3 6473866 445643 439492
34
Infliximab Approved Phase 4 170277-31-3
35
Azathioprine Approved Phase 4 446-86-6 2265
36
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 50-18-0, 6055-19-2 2907
37
Methotrexate Approved Phase 4,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
38
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
39
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
40
Dalteparin Approved Phase 4 9005-49-6
41
Enoxaparin Approved Phase 4 9005-49-6 772
42
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 2078-54-8 4943
43
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
44
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
45
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
46
Homatropine Approved Phase 4 87-00-3
47
Azithromycin Approved Phase 4 83905-01-5 447043 55185
48
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
49
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
50
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838

Interventional clinical trials:

(show top 50) (show all 1313)
# Name Status NCT ID Phase Drugs
1 Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery Unknown status NCT01382641 Phase 4
2 A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery Unknown status NCT02843594 Phase 4
3 Effect of Gabapentin on Pain of the Second Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
4 Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens Unknown status NCT01615861 Phase 4
5 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
6 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
7 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
8 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
9 Efficacy of Subtenon's Block With Olive Tipped Cannula Unknown status NCT01019018 Phase 4
10 Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
11 Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
12 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
13 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
14 Clinical Evaluation of Toric Intraocular Lens Made by Aurolab Unknown status NCT01396616 Phase 4
15 Efficacy Comparison Study of Steroids to Control Post-operative Inflammation Unknown status NCT01801774 Phase 4 Subtenon 20-mg triamcinolone injection;Placebo
16 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
17 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
18 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
19 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
20 Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery Completed NCT02023437 Phase 4
21 Aphakia Versus Pseudophakia in Children Under 2 Years Undergoing Bilateral Congenital Cataract Surgery Completed NCT01297153 Phase 4
22 A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery Completed NCT01769313 Phase 4
23 Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure Completed NCT01971177 Phase 4
24 Size Progression of Macular Degeneration After Cataract Surgery Completed NCT01165801 Phase 4
25 To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery. Completed NCT00763360 Phase 4 Healon;Amvisc Plus
26 Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery Completed NCT00986076 Phase 4 Enoxaparin;Balanced Salt Solution
27 Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial Completed NCT03886779 Phase 4 Bromfenac;Nepafenac
28 Dexmedetomidine vs. Propofol for Cataract Surgery Completed NCT00786370 Phase 4 dexmedetomidine;Propofol;Dexemedetomidine
29 Comparison of Toric IOL Implantation and Opposite Clear Corneal Incision During Cataract Surgery to Correct Corneal Astigmatism Completed NCT01763151 Phase 4
30 Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery Completed NCT00870103 Phase 4 Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
31 Co-Axial Micro-Incision Versus Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System Completed NCT01261975 Phase 4
32 Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients Completed NCT01859702 Phase 4 Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
33 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery Completed NCT01455233 Phase 4 besivance;vigamox
34 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
35 Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery Completed NCT00575380 Phase 4 AzaSite Eye Drops;Vigamox Eye Drops
36 Protein Profile of Immunoregulatory Factors in Diabetic Cataract Completed NCT01832311 Phase 4 Ketorolac
37 Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care Completed NCT00698724 Phase 4 Xibrom, and Optive;Xibrom and Pred Forte
38 A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at Kaduna, Nigeria Completed NCT02150460 Phase 4
39 Laser Cataract Surgery With the Femtosecond Laser Technology Completed NCT01382823 Phase 4
40 Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery Completed NCT01542190 Phase 4 Ketorolac Tromethamine
41 Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions Completed NCT01298973 Phase 4 Viscoat;Saline
42 Spherical Aberration and Contrast Sensitivity in IOLs Completed NCT00576485 Phase 4
43 Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery Completed NCT00758199 Phase 4 Bromfenac;Moxifloxacin hydrochloride;Prednisolone Acetate
44 Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery Completed NCT01383057 Phase 4
45 Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification Completed NCT00673803 Phase 4
46 Prospective Comparison of Epinephrine and Phenylephrine/Ketorolac (Omidria®) Additives With Regards to Intraoperative Pupil Size Completed NCT02895035 Phase 4 Phenylephrine-ketorolac;Epinephrine
47 Comparison of Visual Outcomes and Patient Satisfaction After Cataract Surgery and Implantation of ReSTOR and ReZoom IOLs Completed NCT00366587 Phase 4
48 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects Completed NCT00469690 Phase 4 Acular, Xibrom
49 Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery Completed NCT00348582 Phase 4 Ketorolac, Nepafenac
50 Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery. Completed NCT01244334 Phase 4 Difluprednate ophthalmic emulsion 0.05%;Prednisolone acetate 1%

Search NIH Clinical Center for Cataract

Cochrane evidence based reviews: cataract

Sources

Genetic Tests for Cataract

About this section

Genetic tests related to Cataract:

# Genetic test Affiliating Genes
1 Cataract 30
Sources

Anatomical Context for Cataract

About this section

MalaCards organs/tissues related to Cataract:

42
Eye, Endothelial, Testes, Bone, Heart, Skin, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cataract:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Lens Affected by disease
Sources

Publications for Cataract

About this section

Articles related to Cataract:

(show top 50) (show all 8959)
# Title Authors Year
1
Risk factors associated with persistent anterior uveitis after cataract surgery. ( 30794788 )
2019
2
Effect of a patient-information video on the preoperative anxiety levels of cataract surgery patients. ( 30709627 )
2019
3
Effects of Emotional Stability on Insomnia through Anxiety in Patients with Cataracts. ( 30605992 )
2019
4
Thermocautery Capsulotomy in a Child with Juvenile Arthritis-Related Cataract. ( 30919399 )
2019
5
Trial-based cost-effectiveness analysis of toric versus monofocal intraocular lenses in cataract patients with bilateral corneal astigmatism in the Netherlands. ( 30471848 )
2019
6
Influence of peripheral corneal relaxing incisions during cataract surgery for corneal astigmatism up to 2.5 dioptres on corneal densitometry. ( 30602756 )
2019
7
Gender-differences in age-related changes of corneal astigmatism in Korean cataract patients. ( 30678644 )
2019
8
Efficacy of 4-Haptic Bitoric Intraocular Lens Implantation in Asian Patients with Cataract and Astigmatism. ( 30746910 )
2019
9
Consensus on the management of astigmatism in cataract surgery. ( 30809088 )
2019
10
Correcting astigmatism at the time of cataract surgery: Toric IOLs and corneal relaxing incisions planned with an image-guidance system and intraoperative aberrometer versus manual planning and surgery. ( 30902431 )
2019
11
Comparison of visual quality in cataract patients with low astigmatism after ART2 or ReSTOR intraocular lens implantation. ( 30918811 )
2019
12
Utilizing intraoperative aberrometry and digital eye tracking to develop a novel nomogram for manual astigmatic keratotomy to effectively decrease mild astigmatism during cataract surgery. ( 30993064 )
2019
13
Management of astigmatism during cataract surgery. ( 31030772 )
2019
14
Loss-of-function mutations in TDRD7 lead to a rare novel syndrome combining congenital cataract and nonobstructive azoospermia in humans. ( 31048812 )
2019
15
Triple procedure for pseudophakic bullous keratopathy in complicated cataract surgery: Glued IOL with single-pass four-throw pupilloplasty with pre-Descemet's endothelial keratoplasty. ( 30819560 )
2019
16
Auckland Cataract Study III: Refining Preoperative Assessment With Cataract Risk Stratification to Reduce Intraoperative Complications. ( 30935475 )
2019
17
Auckland Cataract Study III: Refining Preoperative Assessment With Cataract Risk Stratification to Reduce Intraoperative Complications. ( 30935477 )
2019
18
How stressful is cataract surgery for consultants and ophthalmic trainees? Phacoemulsification is a stressful experience for young consultants. ( 30936422 )
2019
19
One-year outcomes following implantation of second-generation trabecular micro-bypass stents in conjunction with cataract surgery for various types of glaucoma or ocular hypertension: multicenter, multi-surgeon study. ( 30936680 )
2019
20
Barriers for Cataract Treatment among Elderly in Sri Lanka. ( 30941168 )
2019
21
Video recording and light intensity change analysis during cataract surgery using an animal model. ( 30941512 )
2019
22
Prophylactic treatment of intraocular pressure elevation after uncomplicated cataract surgery in nonglaucomatous eyes - a systematic review. ( 30941916 )
2019
23
Whole-exome sequencing identified ARL2 as a novel candidate gene for MRCS (microcornea, rod-cone dystrophy, cataract, and posterior staphyloma) syndrome. ( 30945270 )
2019
24
Influence of Posterior Subcapsular Cataract on Structural OCT and OCT Angiography Vessel Density Measurements in the Peripapillary Retina. ( 30946711 )
2019
25
Protective effect of glycine in streptozotocin-induced diabetic cataract through aldose reductase inhibitory activity. ( 30947017 )
2019
26
Visual Performance after a Unilateral or Bilateral Implantation of Enlarged Depth-of-Focus Intraocular Lens in Patients with Cataract: A Prospective Clinical Trial. ( 30949362 )
2019
27
Assessment of Automated Identification of Phases in Videos of Cataract Surgery Using Machine Learning and Deep Learning Techniques. ( 30951163 )
2019
28
Long-term outcomes of patients with myopic traction maculopathy after phacoemulsification for incident cataract. ( 30952957 )
2019
29
Cystoid macular oedema following cataract surgery: A review. ( 30953417 )
2019
30
High rate of recurrence of herpes zoster-related ocular disease after phacoemulsification cataract surgery. ( 30954337 )
2019
31
Asteroid hyalosis prolapse in the anterior chamber after cataract surgery. ( 30954967 )
2019
32
Cataract extraction in patients with primary congenital glaucoma. ( 30957520 )
2019
33
Differences in Cataract Surgery Rates Based on Dementia Status. ( 30958371 )
2019
34
Outcomes of resident-performed small incision cataract surgery in a university-based practice in the USA. ( 30962673 )
2019
35
Prevention of α-crystallin glycation and aggregation using l-lysine results in the inhibition of in vitro catalase heat-induced-aggregation and suppression of cataract formation in the diabetic rat. ( 30965074 )
2019
36
The impact of corneal guttata on the results of cataract surgery. ( 30967299 )
2019
37
Incidence of posterior capsule tears in bimanual vs single-piece irrigation and aspiration during cataract surgery. ( 30968508 )
2019
38
Complications in the first 10 phacoemulsification cataract surgeries with and without prior simulator training. ( 30970123 )
2019
39
Higher TGF-β2 Level in the Aqueous Humor of the Second Eye Versus the First Eye in the Course of Sequential Cataract Surgery. ( 30973281 )
2019
40
Acute Phacolytic Glaucoma and Morgagnian Cataract. ( 30973585 )
2019
41
Visual Acuity Outcomes after Cataract Surgery: High- vs. low-volume surgeons. ( 30974182 )
2019
42
Preoperative fasting for ambulatory cataract surgery: asystematic review. ( 30975334 )
2019
43
Mapping the landscape of cataract surgery teaching assessment in Canadian residency programs. ( 30975336 )
2019
44
Steroid Induced Cataract in Langerhans Cell Histiocytosis Patient. ( 30976354 )
2019
45
Objective assessment of intraoperative technical skill in capsulorhexis using videos of cataract surgery. ( 30977091 )
2019
46
Repeatability and Agreement of a Swept-Source Optical Coherence Tomography-Based Biometer IOLMaster 700 Versus a Scheimpflug Imaging-Based Biometer AL-Scan in Cataract Patients. ( 30985487 )
2019
47
Refractive cataract surgery - what we were, what we are, and what we will be: A personal experience and perspective. ( 30993061 )
2019
48
A novel minimal fluid technique for effective and safe lens hydrodissection during cataract surgery. ( 30993067 )
2019
49
Preparation, Characterization and Antioxidant Evaluation of Poorly Soluble Polyphenol-Loaded Nanoparticles for Cataract Treatment. ( 30993475 )
2019
50
Comparison of refractive predictability and endothelial cell loss in femtosecond laser-assisted cataract surgery and conventional phaco surgery: prospective randomised trial with 6 months of follow-up. ( 30997403 )
2019
Sources

Variations for Cataract

About this section

ClinVar genetic disease variations for Cataract:

6 (show top 50) (show all 273)
# Gene Variation Type Significance SNP ID Assembly Location
1 IARS2 NM_018060.3(IARS2): c.2726C> T (p.Pro909Leu) single nucleotide variant Pathogenic rs587783070 GRCh38 Chromosome 1, 220143109: 220143109
2 IARS2 NM_018060.3(IARS2): c.2726C> T (p.Pro909Leu) single nucleotide variant Pathogenic rs587783070 GRCh37 Chromosome 1, 220316451: 220316451
3 EPM2A NM_005670.3(EPM2A): c.376A> G (p.Ile126Val) single nucleotide variant Conflicting interpretations of pathogenicity rs150452237 GRCh37 Chromosome 6, 146007358: 146007358
4 EPM2A NM_005670.3(EPM2A): c.376A> G (p.Ile126Val) single nucleotide variant Conflicting interpretations of pathogenicity rs150452237 GRCh38 Chromosome 6, 145686222: 145686222
5 PITX2 NM_153427.2(PITX2): c.660G> A (p.Pro220=) single nucleotide variant Benign/Likely benign rs148191851 GRCh37 Chromosome 4, 111539437: 111539437
6 PITX2 NM_153427.2(PITX2): c.660G> A (p.Pro220=) single nucleotide variant Benign/Likely benign rs148191851 GRCh38 Chromosome 4, 110618281: 110618281
7 PITX2 NM_153427.2(PITX2): c.*454C> T single nucleotide variant Benign rs6533526 GRCh38 Chromosome 4, 110617671: 110617671
8 PITX2 NM_153427.2(PITX2): c.*454C> T single nucleotide variant Benign rs6533526 GRCh37 Chromosome 4, 111538827: 111538827
9 PITX2 NM_153427.2(PITX2): c.403G> A (p.Ala135Thr) single nucleotide variant Benign/Likely benign rs77144743 GRCh37 Chromosome 4, 111539694: 111539694
10 PITX2 NM_153427.2(PITX2): c.403G> A (p.Ala135Thr) single nucleotide variant Benign/Likely benign rs77144743 GRCh38 Chromosome 4, 110618538: 110618538
11 CRYGD NM_006891.3(CRYGD): c.*12T> C single nucleotide variant Benign rs2305429 GRCh37 Chromosome 2, 208986385: 208986385
12 CRYGD NM_006891.3(CRYGD): c.*12T> C single nucleotide variant Benign rs2305429 GRCh38 Chromosome 2, 208121661: 208121661
13 CRYGD NM_006891.3(CRYGD): c.285A> G (p.Arg95=) single nucleotide variant Benign rs2305430 GRCh37 Chromosome 2, 208986637: 208986637
14 CRYGD NM_006891.3(CRYGD): c.285A> G (p.Arg95=) single nucleotide variant Benign rs2305430 GRCh38 Chromosome 2, 208121913: 208121913
15 CRYGD NM_006891.3(CRYGD): c.51T> C (p.Tyr17=) single nucleotide variant Benign rs2242074 GRCh37 Chromosome 2, 208989037: 208989037
16 CRYGD NM_006891.3(CRYGD): c.51T> C (p.Tyr17=) single nucleotide variant Benign rs2242074 GRCh38 Chromosome 2, 208124313: 208124313
17 BFSP2 NM_003571.3(BFSP2): c.1220C> A (p.Ala407Asp) single nucleotide variant Benign rs79087781 GRCh37 Chromosome 3, 133191385: 133191385
18 BFSP2 NM_003571.3(BFSP2): c.1220C> A (p.Ala407Asp) single nucleotide variant Benign rs79087781 GRCh38 Chromosome 3, 133472541: 133472541
19 PITX2 NM_153427.2(PITX2): c.459T> G (p.Ser153=) single nucleotide variant Benign/Likely benign rs35946364 GRCh37 Chromosome 4, 111539638: 111539638
20 PITX2 NM_153427.2(PITX2): c.459T> G (p.Ser153=) single nucleotide variant Benign/Likely benign rs35946364 GRCh38 Chromosome 4, 110618482: 110618482
21 MIP NM_012064.4(MIP): c.319G> A (p.Val107Ile) single nucleotide variant Benign/Likely benign rs74641138 GRCh38 Chromosome 12, 56454295: 56454295
22 MIP NM_012064.4(MIP): c.319G> A (p.Val107Ile) single nucleotide variant Benign/Likely benign rs74641138 GRCh37 Chromosome 12, 56848079: 56848079
23 HSF4 NM_001538.3(HSF4): c.123+9C> T single nucleotide variant Benign rs115335849 GRCh38 Chromosome 16, 67164943: 67164943
24 HSF4 NM_001538.3(HSF4): c.123+9C> T single nucleotide variant Benign rs115335849 GRCh37 Chromosome 16, 67198846: 67198846
25 46;XY;inv(9)(q22.3q34.11)dn inversion Pathogenic
26 PITX2 NM_153427.2(PITX2): c.480A> T (p.Ser160=) single nucleotide variant Conflicting interpretations of pathogenicity rs141176394 GRCh37 Chromosome 4, 111539617: 111539617
27 PITX2 NM_153427.2(PITX2): c.480A> T (p.Ser160=) single nucleotide variant Conflicting interpretations of pathogenicity rs141176394 GRCh38 Chromosome 4, 110618461: 110618461
28 UPF3B NM_080632.2(UPF3B): c.758T> C (p.Ile253Thr) single nucleotide variant Uncertain significance rs754982440 GRCh37 Chromosome X, 118975088: 118975088
29 UPF3B NM_080632.2(UPF3B): c.758T> C (p.Ile253Thr) single nucleotide variant Uncertain significance rs754982440 GRCh38 Chromosome X, 119841125: 119841125
30 CRYGD NM_006891.3(CRYGD): c.295A> G (p.Arg99Gly) single nucleotide variant Uncertain significance rs886055527 GRCh38 Chromosome 2, 208121903: 208121903
31 CRYGD NM_006891.3(CRYGD): c.295A> G (p.Arg99Gly) single nucleotide variant Uncertain significance rs886055527 GRCh37 Chromosome 2, 208986627: 208986627
32 CRYGD NM_006891.3(CRYGD): c.252+10T> A single nucleotide variant Likely benign rs200111275 GRCh38 Chromosome 2, 208124102: 208124102
33 CRYGD NM_006891.3(CRYGD): c.252+10T> A single nucleotide variant Likely benign rs200111275 GRCh37 Chromosome 2, 208988826: 208988826
34 CRYGD NM_006891.3(CRYGD): c.10-7C> G single nucleotide variant Likely benign rs189582567 GRCh38 Chromosome 2, 208124361: 208124361
35 CRYGD NM_006891.3(CRYGD): c.10-7C> G single nucleotide variant Likely benign rs189582567 GRCh37 Chromosome 2, 208989085: 208989085
36 CRYGD NM_006891.3(CRYGD): c.-40C> T single nucleotide variant Likely benign rs113618781 GRCh38 Chromosome 2, 208124513: 208124513
37 CRYGD NM_006891.3(CRYGD): c.-40C> T single nucleotide variant Likely benign rs113618781 GRCh37 Chromosome 2, 208989237: 208989237
38 CRYGD NM_006891.3(CRYGD): c.482A> G (p.Asn161Ser) single nucleotide variant Uncertain significance rs760434926 GRCh38 Chromosome 2, 208121716: 208121716
39 CRYGD NM_006891.3(CRYGD): c.482A> G (p.Asn161Ser) single nucleotide variant Uncertain significance rs760434926 GRCh37 Chromosome 2, 208986440: 208986440
40 CRYGD NM_006891.3(CRYGD): c.252+7A> G single nucleotide variant Likely benign rs185860020 GRCh38 Chromosome 2, 208124105: 208124105
41 CRYGD NM_006891.3(CRYGD): c.252+7A> G single nucleotide variant Likely benign rs185860020 GRCh37 Chromosome 2, 208988829: 208988829
42 CRYGD NM_006891.3(CRYGD): c.130A> G (p.Met44Val) single nucleotide variant Benign/Likely benign rs61731517 GRCh38 Chromosome 2, 208124234: 208124234
43 CRYGD NM_006891.3(CRYGD): c.130A> G (p.Met44Val) single nucleotide variant Benign/Likely benign rs61731517 GRCh37 Chromosome 2, 208988958: 208988958
44 CRYGD NM_006891.3(CRYGD): c.-80A> C single nucleotide variant Uncertain significance rs886055528 GRCh38 Chromosome 2, 208124553: 208124553
45 CRYGD NM_006891.3(CRYGD): c.-80A> C single nucleotide variant Uncertain significance rs886055528 GRCh37 Chromosome 2, 208989277: 208989277
46 XDH NM_000379.3(XDH): c.3647C> A (p.Pro1216His) single nucleotide variant Uncertain significance rs143981573 GRCh38 Chromosome 2, 31339616: 31339616
47 XDH NM_000379.3(XDH): c.3647C> A (p.Pro1216His) single nucleotide variant Uncertain significance rs143981573 GRCh37 Chromosome 2, 31562482: 31562482
48 CRYGD NM_006891.3(CRYGD): c.499C> T (p.Leu167=) single nucleotide variant Likely benign rs774626835 GRCh38 Chromosome 2, 208121699: 208121699
49 CRYGD NM_006891.3(CRYGD): c.499C> T (p.Leu167=) single nucleotide variant Likely benign rs774626835 GRCh37 Chromosome 2, 208986423: 208986423
50 CRYGD NM_006891.3(CRYGD): c.376G> A (p.Val126Met) single nucleotide variant Likely benign rs150318966 GRCh38 Chromosome 2, 208121822: 208121822

Copy number variations for Cataract from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 86882 14 67000000 106368585 Copy number cataract
2 89231 15 17000000 100338915 Copy number cataract
3 106728 17 1 11200000 Copy number cataract
Sources

Expression for Cataract

About this section
Search GEO for disease gene expression data for Cataract.
Sources

Pathways for Cataract

About this section

Pathways related to Cataract according to KEGG:

38
# Name Kegg Source Accession
1 Protein processing in endoplasmic reticulum hsa04141
Sources

GO Terms for Cataract

About this section

Cellular components related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction GO:0005921 8.96 GJA3 GJA8
2 connexin complex GO:0005922 8.62 GJA3 GJA8

Biological processes related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.5 CRYAA CRYBA1 CRYBB3 CRYGC CRYGD GJA3
2 camera-type eye development GO:0043010 9.43 CRYAB GJA8 LIM2
3 negative regulation of intracellular transport GO:0032387 9.16 CRYAA CRYAB
4 lens development in camera-type eye GO:0002088 9.1 CRYAB CRYBA1 CRYGD CRYGS GJA8 LIM2

Molecular functions related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of eye lens GO:0005212 9.23 CRYAA CRYAB CRYBA1 CRYBB3 CRYGC CRYGD
2 gap junction channel activity GO:0005243 8.65 GJA8
Sources

Sources for Cataract

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....